Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.

Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM.

Oncotarget. 2018 May 4;9(34):23482-23493. doi: 10.18632/oncotarget.25235. eCollection 2018 May 4.

2.

Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.

Cipriani NA, Blair EA, Finkle J, Kraninger JL, Straus CM, Villaflor VM, Ginat DT.

Int J Surg Pathol. 2017 Oct;25(7):613-618. doi: 10.1177/1066896917709350. Epub 2017 May 12.

PMID:
28497708
3.

Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.

Iams WT, Villaflor VM.

World J Surg. 2017 Jul;41(7):1719-1725. doi: 10.1007/s00268-017-3959-x. Review.

PMID:
28271259
4.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.

5.

MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Topic: Medical Oncology.

Thomas M, Page R, Gressot L, Daniel D, Morgensztern D, Levy B, Hussein M, Razaq M, Villaflor VM, Aix SP, Sivarajan K, Engel-Riedel W, Staib P, Ko A, Ong TJ, Trunova N, Spigel DR.

J Thorac Oncol. 2016 Nov;11(11S):S269. doi: 10.1016/j.jtho.2016.09.035. Epub 2016 Oct 28. No abstract available.

6.

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.

Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ.

Oncotarget. 2017 Jan 31;8(5):8910-8920. doi: 10.18632/oncotarget.13315. Review.

7.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.

PMID:
27511844
8.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

9.

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.

Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739.

10.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.

PMID:
26884588
11.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12.

12.

Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature.

Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM.

Dis Esophagus. 2015 Nov-Dec;28(8):772-81. doi: 10.1111/dote.12276. Epub 2014 Aug 21. Review.

PMID:
25142531
13.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

14.

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.

Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R.

J Carcinog. 2013 Oct 28;12:20. doi: 10.4103/1477-3163.120632. eCollection 2013.

15.

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Villaflor VM, Salgia R.

J Carcinog. 2013 Mar 18;12:7. doi: 10.4103/1477-3163.109253. Print 2013.

16.

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB.

J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19.

17.

Multidisciplinary approach for patients with esophageal cancer.

Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG.

World J Gastroenterol. 2012 Dec 14;18(46):6737-46. doi: 10.3748/wjg.v18.i46.6737. Review.

18.

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.

19.

Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.

Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK.

J Thorac Oncol. 2012 Feb;7(2):376-81. doi: 10.1097/JTO.0b013e31824166a5.

20.

Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR.

Cancer. 2012 Jun 1;118(11):2962-70. doi: 10.1002/cncr.26611. Epub 2011 Oct 21.

Supplemental Content

Loading ...
Support Center